Ovarian Cancer | Clinical

May 16, 2021

Melissa Hardesty, MD, discusses the modern disease management of patients with ovarian cancer in the community setting.

May 11, 2021

Melissa, K. Frey, MD, the study of adequate collection of family cancer history in ovarian and other gynecological cancers in order to determine cancer risk and early interventions.

May 08, 2021

In an interview with Targeted Oncology, William H. Bradley, MD, discussed the results of the SOLO-1 trial of olaparib as a maintenance therapy for patients with ovarian cancer with a BRCA1/2 mutation, and other developments in the ovarian cancer field.

May 03, 2021

In an interview with Targeted Oncology, Ursula A. Matulonis, MD, discusses results from further follow-up of patients with ovarian cancer treated in the ENGOT-OV16/NOVA.

April 27, 2021

A leader in gynecologic oncology, Chirag Shah, MD, MPH, provides insight into the future of ovarian cancer by discussing the potential for immunotherapy, TP53 inhibition, and novel therapeutics on the horizon.

April 27, 2021

Chirag Shah, MD, MPH, discusses platinum sensitivity vs resistance impact treatment selection in subsequent lines of therapy.

April 27, 2021

An expert in gynecologic oncology reviews the PRIMA and NOVA clinical trials and discusses their implications for the management of ovarian cancer.

April 27, 2021

Chirag Shah, MD, MPH, provides key insights into factors to consider when counseling patients with ovarian cancer on the available treatment options for maintenance therapy.

April 27, 2021

Key opinion leader in obstetrics and gynecology Chirag Shah, MD, MPH, discusses best practices for molecular testing and genetic counseling for patients with newly diagnosed or relapsed ovarian cancer.

April 27, 2021

Chirag Shah, MD, MPH shares insight into factors influencing the prognosis of patients with ovarian cancer.